Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stevia Corp. Announces Appointment of the Former Chief Science Officer for Quest Diagnostics to its Scientific Advisory Panel
Press Release | 06/14/2022
NEW YORK, NY / ACCESSWIRE / June 14, 2022 / Stevia Corp. (OTC PINK:STEV) ("Stevia Corp" or the "Company"), a healthcare company focused on the commercial development of products that support a healthy lifestyle announced today the appointment of David L. Cooper, Ph.D.. M.D., CEO and Founder of PhytoMedical Solutions, LLC and PhytoDental Solutions, LLC to its scientific advisory panel. Dr. Cooper received his Ph.D. in Chemistry from Florida State University and his M.D. from the University of Florida.
Dr. Cooper served originally as the Chief Science Officer and Chief Operating Officer for Quest Diagnostics Nichols Institute and later as Chief Science Officer of Quest Diagnostics (DGX:NYSE). The Nichols Institute, a wholly-owned division of Quest Diagnostics, is the premier reference lab for Quest Diagnostics. The Nichols Institute is also known as one of the premier reference labs in the entire world (Nichols Institute: The Quest Diagnostics Advantage - YouTube)
While at Quest Diagnostics, Dr. Cooper coordinated the Nichols Institute's move for Quest to an ISO 9001 Company, expanded their HIV and Genetic Testing, and reorganized the Nichols Institute Research and Test Development efforts into a clinical specialty focus. Dr. Cooper also assisted in opening new markets for Quest Diagnostics in Asia, South America and Europe.
Dr. Cooper subsequently served as Chief Medical Officer of NimbleGen Systems Inc. While at NimbleGen Systems, Dr. Cooper established NimbleGen Systems of Iceland, LLC, which manufactured custom DNA arrays and related services to the scientific research marketplace worldwide. Dr. Cooper also served as Senior Scientific Advisor to Visible Genetics, Inc. of Toronto, Canada, where he assisted with the development of the TRUGENE TM HIV-1 Genotyping Kit, the first FDA approved drug resistance test for routine clinical use.
In academia, Dr. Cooper has held tenured Pathology faculty positions at Duke University Medical Center and the University of Pittsburgh Medical Center. While Professor of Molecular Pathology at Duke and UPMC, Dr. Cooper's research focused on defining the various isoforms and role of CD44 in tumor metastasis. His original research continues to be highly regarded and regularly referenced as CD44 therapeutics have moved into clinical trials. While at the University of Pittsburgh, he founded the first division of Molecular Pathology in the United States, assisted in founding and served as the first President of the Association for Molecular Pathology (AMP), and was editor and founder of the journal, Molecular Diagnosis - "A journal devoted to the understanding of human disease through the clinical application of molecular biology." His academic honors include the prestigious Lichfield Lectureship, Oxford University, Oxford, England. Dr. Cooper is the author of more than 100 scientific and medical publications in molecular diagnostics, infectious disease, hematology, cancer, human genetics, pediatrics, precision medicine and the development of novel gene therapies which were supported by numerous grants including grants from the National Institutes of Health, the American Cancer Society and the Department of Defense Breast Cancer Initiative. Dr. Cooper continues to be active publishing his most recent clinical research in three manuscripts in the international, peer reviewed, open access Journal Clinics in Medicine (ISSN: 2688-6731) in the last year.
Dr. Cooper has also had a key advisory role in substantial medical devices which resulted in commercially successful products and/or acquisitions by major pharmaceutical and medical technology companies.
As Senior Medical Advisor to Visible Genetics (Toronto), he oversaw TRUGENE HIV-1 DNA sequencing format which was the first commercial FDA approved sequencing kit to detect HIV resistance. To commercialize and distribute products in the U.S., he created "The Gene Foundry" as a spinoff which successfully distributed TruGene apparatus and kits throughout the U.S. Visible Genetics and TRUGENE were subsequently acquired by Bayer for $61.4 Million US.
Built and managed the NimbleGen microarray technology in Reykjavik, Icelandutilizing photosynthesis chemistry. The facility served both European and U.S. investigators with DNA chips designed uniquely for each investigative purpose. Dr. Cooper built the staff to 20 members located in Iceland. NimbleGen was acquired by Roche for $250 Million U.S.
Dr. Cooper designed the physical layoutand personnel requirements for CODIS mass spec laboratory for IBIS Biosciences. Ibis was acquired by Abbott and led to development of IBIS TIGER/T5000 Universal Biosensor platform. Purchase price was in excess of $220 M US.
As actingCMO of Eragen, Dr. Cooper oversaw the early work which led to FDA 510K approval of their HSV assay and assisted in development of the constituents of a viral respiratory panel later taken to market by Luminex which acquired EraGen for $25M US and stock incentives.
Designed and hired original Laboratory Director for Affymetrix's 10,000 sq foot CLIA Laboratory in Sacramento, CA. Laboratory was later transferred and acquired by Navigenics under undisclosed financialterms in excess of $100M US.
As CSO Quest Diagnostics, oversaw portfolio development of 80-100 new and reworked assays yearly. Instituting first in man diagnostics across infectious disease, endocrinology, cardiology, respiratory disease and cancer.
As an outside advisor, formed Qiagen's original Clinical Advisory Board from which the internationally leading blood product stabilizing nucleicacids PAXgene RNA and DNA and other products originated.
Kenneth Maciora, Chairman and Chief Executive Officer of Stevia Corp. said, "We are ecstatic that Dr. Cooper has accepted our invitation to join our Advisory Panel. Dr. Cooper's academic and commercial achievements are well known by people that have worked with him over the years. His knowledge and advice as we launch our business plan will be invaluable to Stevia Corp. and I am beyond thrilled that Dr. Cooper will be part of our plan."
Mr. Maciora added, "The current formulation development and clinical research that Dr. Cooper and his colleagues are doing with cannabinoids in dental sciences and the links between dental and systemic disease is ground breaking. As we launch our products, we will have further discussions with Dr. Cooper about his current work and a possible collaboration between his company and Stevia Corp. Dr. Cooper has the vision to do quality research and is engaging in real science to explore how cannabinoids can improve dental health and possibly affect the re-generation of tissue damaged by periodontitis and gingivitis."
Dr. Cooper commented, "I am honored to join Stevia's effort to develop natural health products. The development of an association with Stevia Corp. is a natural fit as my interest in plant and natural products for health has grown over my career in chemistry, medicine and pharmaceuticals. This is an exciting time for Stevia Corp and I'm looking forward to contributing my experience and expertise."
CDEL is smart
Feels like a crap shoot here. Been watching for a few weeks but not feeling all warm and fuzzy. Company more than likely will have to do a split in order to meet the price minimum and avoid delisting. Hopefully it can stay above .70.
He's been putting in the work for many months now. Progress is happening but obviously not as fast as we all had hoped for. I firmly believe shareholders will be rewarded here for their patience. Those that think it's a crap ticker can move on to bigger and better things.
I added a few at .0087 and .0093. With only a few seconds left before the close someone bidwhacked. Almost like someone wants it to stay down. Eventually people will wish they loaded these sub .01 shares IMO
I'm liking how this is trading...ready to see it bust back into pennyland.
I'm very curious to see who will be on this "advisory panel" mentioned in the PR
Nice!! I’m flying blind without L2 for a while now.
I made a killing on a few plays in the past so it’s all just from gambling winnings (BZWR, MTRT, MKGP, etc). I’ve had regular communication with the company and believe in their vision.
I don't believe it'll sink but can't state 100% that anything is guaranteed to run. I'm invested heavily and plan on seeing where this adventure goes. I believe they chose this path for a reason and didn't just pick it out of thin air.
There are many “turds” in the OTC with billions of shares that run hard and defy logic. This one is clean and has a clear business plan. Will it run hard or sink? Time will tell but it’s no “turd”.
LOL we all have our own opinions. Have to say I’ve never once gone on an Ihub board to make a statement like that. I may think a stock is crap but wouldn’t want to see others lose money. It I don’t like it, wouldn’t spend my time posting on it.
Bingo!! Making moves with the shareholders in mind and has good understanding of how the OTC works.
Sometimes people take a loss and then resent that company. The worst feeling is selling then later seeing that same stock run with out you. Can’t say I’d stick around after I sold out of something.
It takes money to raise money so obviously restricted shares would need to be issued. It’s the convertible debt with bad terms that end up effecting pps…that isn’t the case here.
Very thorough and well thought out release. As someone that has been buying prostate support supplements for past couple years I know there is a big market for this. It's one of those few supplements that you really notice a difference rather than just being in your head. Always a market for stevia sweetener so am glad to see them continuing that.
Ken and the crew have the shareholders best interested as priority and believe something special is building here. How many companies down here can say they've eliminated toxic debt? Most just keep issuing it then do an RS and repeat.
agreed! I'm ready to see this back over .01
eh...who's counting. No rushing greatness LOL
It’s just a stock…not like it’s life or death situation. If it runs great…if not, oh well.
Exactly! Most of the crap down here just pumps to run their printing press.
It's unfortunate what the prior CEO did here Ken really wants to build some shareholder value. He has put in his own time and money and been successful in eliminating debt while raising capital via private placement.
I’ve got a very nice stock pile of shares and believe you’ll be pleasantly surprised by this stock. Many “junk” tickers have had their day in the sun and turned things around.
So jealous! Maybe when this takes off I could roll some profits into my own boat...or at least go on a long cruise.
It’ll come when it comes.
Only a few of us keeping up with the company and even bother posting on this board which nobody seems to read. That can all change in a heartbeat once company breaks their silence and issues a PR.
Happy with the close on Friday at .0092. Bid/ask tightened up to .0085 x .0092 and saw another large bid at 660K shares. This is after someone scored 500K bid sitting.
I'm currently down on my investment here but pretty much everything I'm in is down over the past few months. I've had conversations with the CEO on regular basis so am comfortable holding here.
No reason for people to buy the rumor...only people that know about this are those that follow their twitter and most are already in. There have definitely been some bid sitters absorbing up all they can though.
You are correct in that there is no business here and with that said it still went to almost .03.
CEO has been working to role a business in here and has spent his own time and money. They also raised $100K in private placement with shares between .006 and .008
The spread is .0076 x .0092 and currently at .0084. This is pretty thinly traded other than occasional flipper. $STEV under the radar aside from a few longs like me. Once company has operations no reason for price to stay down here.
would be nice to be back to pennyland before the news but happy if we can stay around here
Pretty much everything from stocks to crypto have been trending down. Been rough out here.
With Ken putting in his own time and money to clean this up, his steadfastness to build something for shareholders and understanding of how the OTC operates...I'm willing to wait it out.
Nice to see another green day here
NIce!! Anything down here feels like a deal to me. I've got a large boatload of shares and fell Ken will deliver the goods for the shareholders.
I get excited seeing any buying here LOL. I'd probably buy more down here if I had the extra funds.
Snoozefest 2022
LOL..seriously! Bring on those allergies
It stinks but majority of stocks are in the same boat. Even big boards like AAPL, INTL, DIS, and TSLA at/near 6 month lows too. The market has shifted big time from whenever that comment was made.
This stock has a couple things going for it. No dilution and relatively low share structure. Any acquisition/merger will only add value here. Sure it's been drifting down but nearly every stock has. Same for crypto with bitcoin hitting $26K the other day, well off it's highs.
We've had a few hints of making a new record here it's just slow as molasses.
How is L2 looking?